State Street SPDR S&P Health Care Equipment ETF XHE

La inversión busca proporcionar resultados de inversión que, antes de comisiones y gastos, correspondan generalmente al rendimiento total de un índice derivado del segmento de equipos y suministros de atención médica de un índice compuesto total del mercado de EE. UU. Al buscar seguir el rendimiento del Índice de la Industria Selecta de Equipos de Atención Médica S&P (el "índice"), el fondo emplea una estrategia de muestreo. Generalmente invierte sustancialmente todos, pero al menos el 80%, de sus activos totales en los valores que componen el índice. El índice representa el grupo de la industria de equipos de atención médica del Índice de Mercado Total S&P ("S&P TMI"). El fondo no está diversificado.

Con 11 acciones de XHE (USD 978,12) habrías recibido USD 0,22 en dividendos en los últimos 12 meses.

• Investing.com 23 jun

  Healthcare: Pockets of Alpha

  The healthcare sector, down 3.8% year-to-date and the worst performer among S&P 500 sectors, presents selective opportunities despite weak aggregate earnings growth. While the sector faces headwinds with the lowest forward profit margins and weakest 2026 EPS growth outlook, specific subsectors show promise: Pharmaceuticals are rerating as GLP-1 economics mature, Biotech benefits from M&A activity, and smaller-cap healthcare companies outperform large-cap peers. The recommendation is a market-weight position focusing on areas with improving earnings, margins, and catalysts rather than broad sector exposure.

  

• Benzinga 18 feb

  FDA Expands Approval For Staar Surgical's Popular Implantable Lens

  The FDA approved an expanded age indication for Staar Surgical's EVO/EVO+ Visian Implantable Collamer Lenses, extending eligibility from ages 21-45 to 21-60 years old. This could add nearly 8 million refractive patients to the market. The approval is based on three-year clinical trial data showing strong safety profiles. Despite the positive news, the stock trades 9.8% below its 20-day moving average with bearish technical indicators, though RSI suggests oversold conditions.

  

• Benzinga 15 ene

  STAAR Surgical Stock Falls After Largest Shareholder Broadwood Gains Board Influence

  STAAR Surgical shares declined as Broadwood Partners, which owns 31% of the company, gained board influence with two new directors joining alongside Christopher Wang of Yunqi Capital. The changes follow the failed merger with Alcon and include the departure of Chair Elizabeth Yeu, with CEO Stephen Farrell remaining until January 31, 2026. The stock is trading below key moving averages with mixed technical signals.

  

• Zacks Investment Research 24 jun

  Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

  Sector ETF report for XHE

  

• Benzinga 12 jun

  Haemonetics' Strategic Moves Poised To Boost Margins And Earnings, Says Analyst

  Needham & Co. analyst Mike Matson upgraded Haemonetics Corporation (NYSE:HAE) from Hold to Buy with a price target of $112. The analyst says that Haemonetics has reaffirmed its “high-20%” FY26 operating margin goal. To reach this, the company must improve by approximately 600 basis points from its FY24 margin of 21.1%, writes the analyst. While the analyst earlier doubted the company’s ability to reach this target, the product mix analysis has bolstered their confidence. The analyst has identified two key factors influencing the company’s gross margin, which includes ...Full story available on Benzinga.com